A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT02123758 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: Abiraterone Acetate
DRUG: Prednisone
DRUG: JNJ-56021927

Sponsor

Aragon Pharmaceuticals, Inc.